Compile Data Set for Download or QSAR
Report error Found 378 Enz. Inhib. hit(s) with all data for entry = 2376
TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363393(N-(2-(4-(2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin...)
Affinity DataIC50: 0.920nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363331((S)-4-((5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-...)
Affinity DataIC50: 1.19nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50239948(US9850225, Example 1166 | CHEMBL4071326)
Affinity DataIC50: 1.40nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363278((2S,4R)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(...)
Affinity DataIC50: 1.85nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363373((R)-1-(2-((5-cyanopyridin-3-yl)methoxy)-4-(3-(2,3-...)
Affinity DataIC50: 1.88nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363064(US9850225, Example 1001 | (R)-2-(2-(3-cyanobenzylo...)
Affinity DataIC50: 2.25nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363286((R)-2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 2.71nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363080(US9850225, Example 1016 | (R)-2-((2-((3-cyanobenzy...)
Affinity DataIC50: 4.55nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363303(3-((4-chloro-5-((3-(2,3-dihydrobenzo[b][1,4]dioxin...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363301((S)-2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363305(3-((4-chloro-5-((3-(2,3-dihydrobenzo[b][1,4]dioxin...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363294(2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dih...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363299((2S,3S)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363325((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363322((R)-2-((5-chloro-4-((2-cyano-3-(2,3-dihydrobenzo[b...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363323((R)-2-((5-chloro-4-((2-cyano-3-(2,3-dihydrobenzo[b...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363310(3-((2-((((1H-tetrazol-5-yl)methyl)amino)methyl)-4-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363311((S)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363336(N-(2-(2-((5-bromopyridin-3-yl)methoxy)-5-chloro-4-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363337((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363334((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363335((R)-2-(2-((5-bromopyridin-3-yl)methoxy)-5-chloro-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363340((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363341((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363328(N-(2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363329((R)-2-((5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363326((S)-2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363327((S)-4-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363332(N-(2-((5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363333((S)-2-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363330((R)-2-((5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363352(N-(2-((2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363355((S)-1-(2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363350((R)-2-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrob...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363351((S)-4-((2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363358((S)-2-((2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363359(N-(2-((4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363356((R)-2-((2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363357((S)-2-((2-((3-cyano-4-fluorobenzyl)oxy)-4-((3-(2,3...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363345(N-(2-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobe...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363342((S)-1-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363348((S)-2-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrob...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363349((S)-1-(2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobe...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363346((S)-4-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrob...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363347((S)-2-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrob...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363372((R)-2-(2-((5-cyanopyridin-3-yl)methoxy)-4-(3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363370((S)-1-(2-((5-cyanopyridin-3-yl)methoxy)-4-(3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363371((S)-2-(2-((5-cyanopyridin-3-yl)methoxy)-4-(3-(2,3-...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363376((R)-2-(2-(3-cyanobenzyloxy)-4-(3-(2,3-dihydrobenzo...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM363377(N-(2-(2-(3-cyanobenzyloxy)-4-(3-(2,3-dihydrobenzo[...)
Affinity DataIC50: 5.30nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

Displayed 1 to 50 (of 378 total ) | Next | Last >>
Jump to: